Haemoglobin Mass and Running Time Trial Performance after Recombinant Human Erythropoietin Administration in Trained Men

Jérôme Durussel; Evangelia Daskalaki; Martin Anderson; Tushar Chatterji; Diresibachew H. Wondimu; Neal Padmanabhan; Rajan K. Patel; John D. McClure; Yannis P. Pitsiladis

doi:10.1371/journal.pone.0056151

Haemoglobin Mass and Running Time Trial Performance after Recombinant Human Erythropoietin Administration in Trained Men

Jérôme Durussel
, Evangelia Daskalaki
, Martin Anderson
, Tushar Chatterji
, Diresibachew H. Wondimu
, Neal Padmanabhan
, Rajan K. Patel
, John D. McClure
, Yannis P. Pitsiladis^*

^*Corresponding author for this work

Research output: Contribution to journal › Journal article › peer-review

55 Citations (Scopus)

Abstract

Recombinant human erythropoietin (rHuEpo) increases haemoglobin mass (Hb_mass) and maximal oxygen uptake (v̇ O_{2 max}).

Purpose: This study defined the time course of changes in Hb_mass, v̇ O_{2 max} as well as running time trial performance following 4 weeks of rHuEpo administration to determine whether the laboratory observations would translate into actual improvements in running performance in the field.

Methods: 19 trained men received rHuEpo injections of 50 IU•kg^-1 body mass every two days for 4 weeks. Hb_mass was determined weekly using the optimized carbon monoxide rebreathing method until 4 weeks after administration. v̇ O_{2 max} and 3,000 m time trial performance were measured pre, post administration and at the end of the study.

Results: Relative to baseline, running performance significantly improved by ~6% after administration (10:30±1:07 min:sec vs. 11:08±1:15 min:sec, p<0.001) and remained significantly enhanced by ~3% 4 weeks after administration (10:46±1:13 min:sec, p<0.001), while v̇ O_{2 max} was also significantly increased post administration (60.7±5.8 mL•min^-1•kg^-1 vs. 56.0±6.2 mL•min^-1•kg^-1, p<0.001) and remained significantly increased 4 weeks after rHuEpo (58.0±5.6 mL•min^-1•kg^-1, p = 0.021). Hb_mass was significantly increased at the end of administration compared to baseline (15.2±1.5 g•kg^-1 vs. 12.7±1.2 g•kg^-1, p<0.001). The rate of decrease in Hb_mass toward baseline values post rHuEpo was similar to that of the increase during administration (-0.53 g•kg^-1•wk^-1, 95% confidence interval (CI) (-0.68, -0.38) vs. 0.54 g•kg^-1•wk^-1, CI (0.46, 0.63)) but Hb_mass was still significantly elevated 4 weeks after administration compared to baseline (13.7±1.1 g•kg^-1, p<0.001).

Conclusion: Running performance was improved following 4 weeks of rHuEpo and remained elevated 4 weeks after administration compared to baseline. These field performance effects coincided with rHuEpo-induced elevated v̇ O_{2 max} and Hb_mass.

Original language	English
Article number	e56151
Number of pages	8
Journal	PLoS ONE
Volume	8
Issue number	2
DOIs	https://doi.org/10.1371/journal.pone.0056151
Publication status	Published - 13 Feb 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1371/journal.pone.0056151

Cite this

@article{17b5c33a509946f397847a9ea1a48120,

title = "Haemoglobin Mass and Running Time Trial Performance after Recombinant Human Erythropoietin Administration in Trained Men",

abstract = "Recombinant human erythropoietin (rHuEpo) increases haemoglobin mass (Hbmass) and maximal oxygen uptake ({\.v} O2 max). Purpose: This study defined the time course of changes in Hbmass, {\.v} O2 max as well as running time trial performance following 4 weeks of rHuEpo administration to determine whether the laboratory observations would translate into actual improvements in running performance in the field. Methods: 19 trained men received rHuEpo injections of 50 IU•kg-1 body mass every two days for 4 weeks. Hbmass was determined weekly using the optimized carbon monoxide rebreathing method until 4 weeks after administration. {\.v} O2 max and 3,000 m time trial performance were measured pre, post administration and at the end of the study. Results: Relative to baseline, running performance significantly improved by \textasciitilde{}6\% after administration (10:30±1:07 min:sec vs. 11:08±1:15 min:sec, p<0.001) and remained significantly enhanced by \textasciitilde{}3\% 4 weeks after administration (10:46±1:13 min:sec, p<0.001), while {\.v} O2 max was also significantly increased post administration (60.7±5.8 mL•min-1•kg-1 vs. 56.0±6.2 mL•min-1•kg-1, p<0.001) and remained significantly increased 4 weeks after rHuEpo (58.0±5.6 mL•min-1•kg-1, p = 0.021). Hbmass was significantly increased at the end of administration compared to baseline (15.2±1.5 g•kg-1 vs. 12.7±1.2 g•kg-1, p<0.001). The rate of decrease in Hbmass toward baseline values post rHuEpo was similar to that of the increase during administration (-0.53 g•kg-1•wk-1, 95\% confidence interval (CI) (-0.68, -0.38) vs. 0.54 g•kg-1•wk-1, CI (0.46, 0.63)) but Hbmass was still significantly elevated 4 weeks after administration compared to baseline (13.7±1.1 g•kg-1, p<0.001). Conclusion: Running performance was improved following 4 weeks of rHuEpo and remained elevated 4 weeks after administration compared to baseline. These field performance effects coincided with rHuEpo-induced elevated {\.v} O2 max and Hbmass.",

author = "J{\'e}r{\^o}me Durussel and Evangelia Daskalaki and Martin Anderson and Tushar Chatterji and Wondimu, \{Diresibachew H.\} and Neal Padmanabhan and Patel, \{Rajan K.\} and McClure, \{John D.\} and Pitsiladis, \{Yannis P.\}",

note = "Publisher copyright: {\textcopyright} 2013 Durussel et al.",

year = "2013",

month = feb,

day = "13",

doi = "10.1371/journal.pone.0056151",

language = "English",

volume = "8",

journal = "PLoS ONE",

issn = "1932-6203",

publisher = "Public Library of Science",

number = "2",

}

TY - JOUR

T1 - Haemoglobin Mass and Running Time Trial Performance after Recombinant Human Erythropoietin Administration in Trained Men

AU - Durussel, Jérôme

AU - Daskalaki, Evangelia

AU - Anderson, Martin

AU - Chatterji, Tushar

AU - Wondimu, Diresibachew H.

AU - Padmanabhan, Neal

AU - Patel, Rajan K.

AU - McClure, John D.

AU - Pitsiladis, Yannis P.

PY - 2013/2/13

Y1 - 2013/2/13

N2 - Recombinant human erythropoietin (rHuEpo) increases haemoglobin mass (Hbmass) and maximal oxygen uptake (v̇ O2 max). Purpose: This study defined the time course of changes in Hbmass, v̇ O2 max as well as running time trial performance following 4 weeks of rHuEpo administration to determine whether the laboratory observations would translate into actual improvements in running performance in the field. Methods: 19 trained men received rHuEpo injections of 50 IU•kg-1 body mass every two days for 4 weeks. Hbmass was determined weekly using the optimized carbon monoxide rebreathing method until 4 weeks after administration. v̇ O2 max and 3,000 m time trial performance were measured pre, post administration and at the end of the study. Results: Relative to baseline, running performance significantly improved by ~6% after administration (10:30±1:07 min:sec vs. 11:08±1:15 min:sec, p<0.001) and remained significantly enhanced by ~3% 4 weeks after administration (10:46±1:13 min:sec, p<0.001), while v̇ O2 max was also significantly increased post administration (60.7±5.8 mL•min-1•kg-1 vs. 56.0±6.2 mL•min-1•kg-1, p<0.001) and remained significantly increased 4 weeks after rHuEpo (58.0±5.6 mL•min-1•kg-1, p = 0.021). Hbmass was significantly increased at the end of administration compared to baseline (15.2±1.5 g•kg-1 vs. 12.7±1.2 g•kg-1, p<0.001). The rate of decrease in Hbmass toward baseline values post rHuEpo was similar to that of the increase during administration (-0.53 g•kg-1•wk-1, 95% confidence interval (CI) (-0.68, -0.38) vs. 0.54 g•kg-1•wk-1, CI (0.46, 0.63)) but Hbmass was still significantly elevated 4 weeks after administration compared to baseline (13.7±1.1 g•kg-1, p<0.001). Conclusion: Running performance was improved following 4 weeks of rHuEpo and remained elevated 4 weeks after administration compared to baseline. These field performance effects coincided with rHuEpo-induced elevated v̇ O2 max and Hbmass.

AB - Recombinant human erythropoietin (rHuEpo) increases haemoglobin mass (Hbmass) and maximal oxygen uptake (v̇ O2 max). Purpose: This study defined the time course of changes in Hbmass, v̇ O2 max as well as running time trial performance following 4 weeks of rHuEpo administration to determine whether the laboratory observations would translate into actual improvements in running performance in the field. Methods: 19 trained men received rHuEpo injections of 50 IU•kg-1 body mass every two days for 4 weeks. Hbmass was determined weekly using the optimized carbon monoxide rebreathing method until 4 weeks after administration. v̇ O2 max and 3,000 m time trial performance were measured pre, post administration and at the end of the study. Results: Relative to baseline, running performance significantly improved by ~6% after administration (10:30±1:07 min:sec vs. 11:08±1:15 min:sec, p<0.001) and remained significantly enhanced by ~3% 4 weeks after administration (10:46±1:13 min:sec, p<0.001), while v̇ O2 max was also significantly increased post administration (60.7±5.8 mL•min-1•kg-1 vs. 56.0±6.2 mL•min-1•kg-1, p<0.001) and remained significantly increased 4 weeks after rHuEpo (58.0±5.6 mL•min-1•kg-1, p = 0.021). Hbmass was significantly increased at the end of administration compared to baseline (15.2±1.5 g•kg-1 vs. 12.7±1.2 g•kg-1, p<0.001). The rate of decrease in Hbmass toward baseline values post rHuEpo was similar to that of the increase during administration (-0.53 g•kg-1•wk-1, 95% confidence interval (CI) (-0.68, -0.38) vs. 0.54 g•kg-1•wk-1, CI (0.46, 0.63)) but Hbmass was still significantly elevated 4 weeks after administration compared to baseline (13.7±1.1 g•kg-1, p<0.001). Conclusion: Running performance was improved following 4 weeks of rHuEpo and remained elevated 4 weeks after administration compared to baseline. These field performance effects coincided with rHuEpo-induced elevated v̇ O2 max and Hbmass.

UR - https://www.scopus.com/pages/publications/84873936500

U2 - 10.1371/journal.pone.0056151

DO - 10.1371/journal.pone.0056151

M3 - Journal article

C2 - 23418527

AN - SCOPUS:84873936500

SN - 1932-6203

VL - 8

JO - PLoS ONE

JF - PLoS ONE

IS - 2

M1 - e56151

ER -

Haemoglobin Mass and Running Time Trial Performance after Recombinant Human Erythropoietin Administration in Trained Men

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this